Subscribe

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Omisirge FDA Approved for Patients with Hematologic Malignancies to Reduce Time to Neutrophil Recovery and Infection

Online First - FDA Oncology Update
NEW DRUGS

On April 17, 2023, the FDA approved omidubicel-onlv (Omisirge; Gamida Cell), a substantially modified allogeneic cord blood–based cell therapy, for use in adults and pediatric patients aged ≥12 years with hematologic malignancies who are to receive umbilical cord blood transplant after myeloablative conditioning to reduce the time to neutrophil recovery and the incidence of infection. The FDA granted this approval priority review and breakthrough and orphan drug designations.

“The approval of Omisirge is a significant development in hematopoietic stem-cell transplantation,” said Steven M. Devine, MD, Chief Medical Officer of the National Marrow Donor Program/Be The Match. “Adding Omisirge as a new donor source may help increase access to stem-cell transplant for patients from racially or ethnically diverse backgrounds who struggle to find a fully matched donor in the registry.”

This approval is based on data from the pivotal Study P0501 (NCT02730299), an open-label, multicenter, international, randomized, phase 3 clinical trial that compared 125 patients with hematologic malignancies who received omidubicel or standard unmanipulated cord blood transplant (UCBT) after myeloablative conditioning and prophylaxis with a calcineurin inhibitor and mycophenolate mofetil for graft-versus-host disease (GVHD).

In all, 62 of the study patients were randomized to receive omidubicel and 63 to receive UCBT. A total of 52 patients received omidubicel, with a median CD34+ cell dose of 9 × 106 cells/kg (range, 2.1-47.6 × 106 cells/kg). In the UCBT arm, 56 patients received 1 or 2 units of unmanipulated cord blood (66% received 2 units). In the 42 patients who had a postthaw cell dose, the median CD34+ cell dose was 0.2 × 106 cells/kg (range, 0.0-0.8 × 106 cells/kg). Total body irradiation–based and chemotherapy-based regimens were among the many conditioning regimens used in the study.

The major efficacy measures included time to neutrophil recovery after transplant and the incidence of grade 2 or 3 bacterial infections or grade 3 fungal infections through 100 days after transplant. The median time to neutrophil recovery was 12 days in the omidubicel group (95% confidence interval [CI], 10-15 days) and 22 days in the UCBT group (95% CI, 19-25 days). In the omidubicel and UCBT arms, 87% and 83% of patients, respectively, achieved neutrophil recovery. The incidences of grade 2 or 3 bacterial infections or grade 3 fungal infections through 100 days after transplant were 39% and 60%, respectively, in the 2 groups.

Omidubicel’s prescribing information has a boxed warning for fatal or life-threatening infusion reactions, GVHD, engraftment syndrome, and graft failure. In 117 study patients who received omidubicel for the treatment of any disease, 47% had infusion reactions, 58% had acute GVHD, 35% had chronic GVHD, and 3% had graft failure.

In this study, the most common grade 3 to 5 adverse reactions in patients with hematologic malignancies were pain (33%), mucosal inflammation (31%), hypertension (25%), and gastrointestinal toxicity (19%).

The recommended dose of omidubicel is a cultured fraction, which consists of a minimum of 8 × 108 total viable cells with a minimum of 8.7% CD34+ cells and a minimum of 9.2 × 107 total CD34+ cells, followed by a noncultured fraction that consists of a minimum of 4.0 × 108 total viable cells with a minimum of 2.4 × 107 CD3+ cells.

Related Items
Padcev plus Keytruda Granted Accelerated FDA Approval for Locally Advanced or Metastatic Urothelial Carcinoma
Online First published on April 24, 2023 in FDA Oncology Update
FDA Approved Zynyz for Metastatic or Recurrent Locally Advanced Merkel-Cell Carcinoma
JHOP - April 2023 Vol 13, No 2 published on March 31, 2023 in FDA Oncology Update
FDA Approved Tafinlar plus Mekinist for Pediatric Patients with BRAF V600E Mutation–Positive Low-Grade Glioma
JHOP - April 2023 Vol 13, No 2 published on March 31, 2023 in FDA Oncology Update
FDA Granted Jemperli Regular Approval for dMMR Endometrial Cancer
JHOP - April 2023 Vol 13, No 2 published on March 31, 2023 in FDA Oncology Update
FDA Expanded Eligibility for Verzenio plus Endocrine Therapy in Patients with Early Breast Cancer
JHOP - April 2023 Vol 13, No 2 published on March 31, 2023 in FDA Oncology Update
Trodelvy Now FDA Approved for HR-Positive, HER2-Negative Breast Cancer
JHOP - April 2023 Vol 13, No 2 published on March 31, 2023 in FDA Oncology Update
Orserdu FDA Approved for ER-Positive Advanced or Metastatic Breast Cancer with ESR1 Mutation
JHOP - February 2023 Vol 13, No 1 published on February 27, 2023 in FDA Oncology Update
Jaypirca, a New BTK Inhibitor, Received FDA Accelerated Approval for Relapsed or Refractory Mantle-Cell Lymphoma
JHOP - February 2023 Vol 13, No 1 published on February 27, 2023 in FDA Oncology Update
FDA Approved Lunsumio for Relapsed or Refractory Follicular Lymphoma
JHOP - February 2023 Vol 13, No 1 published on February 27, 2023 in FDA Oncology Update
Adstiladrin, First Adenoviral Vector–Based Gene Therapy, FDA Approved for High-Risk Non–Muscle Invasive Bladder Cancer
JHOP - February 2023 Vol 13, No 1 published on February 27, 2023 in FDA Oncology Update
© Amplity Health. All rights reserved.